1. AbbVie delays generic Rinvoq release until 2037, securing market dominance. 2. Rinvoq sales reached $6 billion last year, growing 50% year-over-year. 3. ABBV stock up 18% this year, trading around $220 per share. 4. Strong financial stability and profit margins position ABBV as a solid investment. 5. Company navigated losses post-Humira, bolstered by Rinvoq and Skyrizi.
The approval of the Rinvoq agreement strengthens AbbVie's market position, similar to prior successes with Humira. Historical stock increases post-significant agreements suggest continued positive price performance.
The article discusses AbbVie's strategic maneuver to protect Rinvoq's market share, potentially impacting future revenue projections and stock performance.
The generic delay enhances AbbVie's competitive edge long-term, paralleling sustained growth previously seen with Humira until its patent expired.